Article Correctness Is Author's Responsibility: NIH study finds lower concentration of PrEP drug in pregnant young women

(NIH/National Institute of Allergy and Infectious Diseases) Among African adolescent girls and young women who took HIV pre-exposure prophylaxis (PrEP) daily, levels of the PrEP drug tenofovir were more than 30% lower in those who were pregnant than in those who had recently given birth. All 40 study participants took PrEP under direct observation, confirming their near-perfect adherence.